Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

11:28 AM ET 8-K
Capital Raise Brookfield Private Equity Fund LP

Brookfield Private Equity Fund Capital Raise of $6.2M

Brookfield Private Equity Fund LP sold unregistered limited partnership units for aggregate consideration of approximately $6.2 million on October 1, 2026. The sale was part of a continuous private offering that has raised approximately $420.6 million for the broader BPE Program since November 2025.

Value
$6.2M
11:03 AM ET
Earnings Call OmniAb, Inc. OABI ▶ Call

OmniAb Earnings Call: Key Takeaways

OmniAb delivered a strong Q3 2026, raising full-year revenue and cash guidance driven by milestone achievements and a major Eli Lilly partnership.

Call
Oct 30, 2026, 8:00 AM ET
10:43 AM ET 8-K
Capital Raise Hashdex Nasdaq CME Crypto Index ETF NCIQ

Hashdex Nasdaq CME Crypto Index ETF Capital Raise

Hashdex Nasdaq CME Crypto Index ETF entered into an Authorized Participant Agreement with Jane Street Capital, LLC. The agreement establishes the procedures for Jane Street to create and redeem baskets of the ETF's common shares, facilitating the fund's ongoing capital issuance and liquidity.

Counterparty
Jane Street Capital, LLC
9:18 AM ET 8-K
M&A Deal Pelthos Therapeutics Inc. PTHS

Pelthos Therapeutics M&A Deal with Castle Creek Biosciences, Inc.

Pelthos Therapeutics has entered into a definitive agreement to acquire Castle Creek Biosciences in a merger transaction. Castle Creek stockholders will receive 5.2 million shares of Pelthos common stock plus potential milestone payments totaling up to $300 million tied to the clinical and commercial success of the D-Fi gene therapy franchise. The deal combines Pelthos' commercial dermatology infrastructure with Castle Creek's late-stage cell and gene therapy platform for rare skin diseases.

Counterparty
Castle Creek Biosciences, Inc.
8:33 AM ET 8-K
Capital Raise OpenWorld, Inc. OPNW

OpenWorld Capital Raise of $3.5M

OpenWorld, Inc. entered into a securities purchase agreement for a $3.5 million registered direct offering with a single institutional investor. The company is selling 2,517,985 shares of common stock at a combined price of $1.39 per share, including accompanying Series A and Series B warrants. Proceeds are intended for real-world asset growth initiatives and general corporate purposes.

Value
$3.5M
Counterparty
Maxim Group LLC
8:31 AM ET 8-K
Capacity Expansion TerraVolt Holdings, Inc. GEDC

TerraVolt Holdings Capacity Expansion: $32.3M Investment

TerraVolt Holdings entered into option agreements to acquire 1,077 acres in Cassia County, Idaho, for the development of a 240 MW gas-powered digital infrastructure campus. The company paid a $150,000 option fee for the site, which is designed to operate behind-the-meter to avoid grid interconnection delays. The total purchase price for the land is approximately $32.31 million ($30,000 per acre), payable in a mix of cash and a convertible secured promissory note.

Value
$32.3M
Counterparty
Wickel Land Company LLP
Term
Option expires Oct 2027
8:31 AM ET 8-K
Partnership Pluri Inc. PLUR

Pluri Partnership with ZEO ScientifiX, Inc.

Pluri Inc. entered into a partnership agreement with ZEO ScientifiX to grant ZEO an exclusive license to manufacture and commercialize Pluri's regenerative medicine portfolio in the United States. In exchange, Pluri will receive a 50% equity stake in ZEO and the right to designate four out of seven board members, while ZEO will receive approximately 9% of Pluri's outstanding common shares.

Counterparty
ZEO ScientifiX, Inc.
8:30 AM ET 8-K
Partnership Zeo ScientifiX, Inc. ZEOX

Zeo ScientifiX Partnership with Pluri Inc.

Zeo ScientifiX entered into a definitive strategic agreement with Pluri Inc. to expand U.S. manufacturing and commercialization of regenerative medicine products. As part of the license-for-equity transaction, Pluri will grant ZEO an exclusive license to its proprietary 3D cell expansion platform in exchange for a 41% equity stake in ZEO and a share swap involving 4% of each company's outstanding stock.

Counterparty
Pluri Inc.
8:17 AM ET 8-K
M&A Deal Organon & Co. OGN

Organon & M&A Deal with Sun Pharmaceutical Industries Limited

Organon & Co. provided a status update on its pending merger with Sun Pharmaceutical Industries Limited, noting that it has suspended customary earnings calls and press releases due to the transaction. The company furnished supplemental non-GAAP financial metrics for the third quarter of 2026 in lieu of a formal earnings release while the merger remains active.

Counterparty
Sun Pharmaceutical Industries Limited
8:03 AM ET 8-K
M&A Deal Azenta, Inc. AZTA

Azenta Signs $71M M&A Deal with SynPlexity Inc.

Azenta acquired SynPlexity Inc., a synthetic biology company specializing in high-throughput gene libraries, and entered into an exclusive licensing and supply agreement with Elegen Corp. for its cell-free DNA manufacturing technology. The combined strategic investments involve an expected capital deployment ranging from $32 million to $71 million to expand Azenta's GENEWIZ gene synthesis capabilities and regional production capacity.

Value
$71M
Counterparty
SynPlexity Inc.
Term
5 years
8:00 AM ET 8-K
Nasdaq/NYSE Compliance Notice Game Your Game Inc. GYGY

Game Your Game Nasdaq/NYSE Compliance Notice

Game Your Game Inc. received a deficiency notice from Nasdaq on October 27, 2026, because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until April 26, 2027, to regain compliance by maintaining a $1.00 closing bid price for at least 10 consecutive business days. Separately, the company appointed Veronica V. Montenegro as an independent director and chairperson of the nominating and corporate governance committee.

Counterparty
Nasdaq
Term
180 days
7:32 AM ET 8-K
M&A Deal Lci Industries LCII

Lci Industries M&A Deal with Patrick Industries, Inc.

LCI Industries announced that its Board of Directors unanimously rejected an unsolicited $101 per share cash acquisition proposal from Monomoy Capital Partners, determining it was not a superior proposal. The company reaffirmed its commitment to its existing merger agreement with Patrick Industries, which is expected to close in the first half of 2027 and generate $150 million in annual cost synergies.

Counterparty
Patrick Industries, Inc.
7:28 AM ET 8-K
M&A Deal Churchill Capital Corp XI AGLT

Churchill Capital Corp XI Signs $465M M&A Deal with Agility Robotics, Inc.

Churchill Capital Corp XI provided a status update on its pending merger with Agility Robotics, announcing an expected gross capital raise of $465 million following the expiration of the redemption deadline. The business combination is expected to close on November 4, 2026, with the combined company trading on Nasdaq under the ticker 'AGLT' starting November 5, 2026.

Value
$465M
Counterparty
Agility Robotics, Inc.
7:06 AM ET 8-K
Clinical Trial Data Acumen Pharmaceuticals, Inc. ABOS

Acumen Pharmaceuticals Clinical Trial Data

Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer’s disease failed to meet its primary endpoint of cognitive and functional decline improvement. The trial also failed key secondary endpoints, leading the company to cease development of sabirnetug and implement cash conservation measures while exploring strategic options.

Term
18 months
6:32 AM ET 8-K
Divestiture LyondellBasell Industries N.V. LYB

LyondellBasell Industries Divestiture to Valero Energy Corporation for $320M

LyondellBasell entered into an agreement to sell its subsidiary Houston Refining, L.P., which includes the former Houston refinery site, to a subsidiary of Valero Energy Corporation for $320.5 million. The transaction follows the company's shutdown of refining operations at the site in February 2025 and is expected to close in the fourth quarter of 2026.

Value
$320M
Counterparty
Valero Energy Corporation

“In an evolving macroeconomic environment, we delivered another quarter of strong earnings and robust cash conversion through disciplined execution underscored by the strength of our global, cost-advantaged portfolio.”

Peter Vanacker, LYB chief executive officer

“We are leveraging the flexibility and resilience of our leaner structure by optimizing feedstocks, directing products to the most attractive markets and aligning operating rates with demand.”

Peter Vanacker, LYB chief executive officer
6:27 AM ET 8-K
M&A Deal Valero Energy Corp VLO

Valero Energy Signs $320M M&A Deal with LyondellBasell Industries N.V.

Valero Energy Corporation has entered into a definitive agreement to acquire the 700-acre Houston refinery facility from LyondellBasell for $320.5 million. Valero plans to restart 165,000 barrels per day of light sweet crude processing capacity at the site by year-end 2027, with future opportunities to invest in heavy sour crude processing. The deal is expected to close by the end of 2026, subject to regulatory approvals.

Value
$320M
Counterparty
LyondellBasell Industries N.V.
6:13 AM ET 8-K
Product Launch Artificial Intelligence Technology Solutions Inc. AITX

Artificial Intelligence Technology Solutions Product Launch

Artificial Intelligence Technology Solutions (AITX) announced that its subsidiary, Robotic Assistance Devices (RAD), will unveil RAIA, a portable solar-powered security tower, on November 9, 2026. The system is designed to ship in two boxes and deploy without a trailer, targeting the $1.49 billion mobile surveillance tower market with rental costs estimated to be up to 70% lower than competitors.

6:08 AM ET 8-K
Nasdaq/NYSE Compliance Notice Armlogi Holding Corp. BTOC

Armlogi Holding Nasdaq/NYSE Compliance Notice

Armlogi Holding Corp. received a notification from Nasdaq confirming it has regained compliance with the $1.00 minimum bid price requirement for continued listing. The company's common stock maintained a closing bid price of at least $1.00 for 10 consecutive business days from October 15 to October 28, 2026.

Counterparty
The Nasdaq Stock Market LLC
6:08 AM ET 8-K
Cybersecurity Incident Revolve Group, Inc. RVLV

Revolve Group Cybersecurity Incident

Revolve Group disclosed a cybersecurity incident involving unauthorized access to its systems where an actor obtained customer names, contact information, and payment card details. The company has remediated the activity, notified law enforcement, and engaged external experts to investigate. Revolve stated the incident has not caused operational disruptions and is not expected to have a material impact on its business.

6:11 PM ET
Earnings Call Ingram Micro Holding Corp INGM ▶ Call

Ingram Micro Holding Earnings Call: Key Takeaways

Ingram Micro delivered record Q3 results with 21% revenue growth, driven by a 160% surge in AI infrastructure and GPU sales, leading to raised full-year guidance.

Call
Oct 29, 2026, 5:00 PM ET
5:27 PM ET 8-K
Capital Raise T3 Defense Inc. DFNS

T3 Defense Capital Raise of $10M

T3 Defense Inc. raised $10 million in gross proceeds through a private placement of 200 units to an accredited investor. Each unit consists of one share of Series B Convertible Preferred Stock and warrants to purchase 14,851 shares of common stock. The company received net proceeds of approximately $6.6 million after deducting placement agent fees and the repayment of an existing term note.

Value
$10M
Counterparty
Dawson James Securities Inc.
5:26 PM ET 8-K
Capital Raise Zoomcar Holdings, Inc. ZCAR

Zoomcar Holdings Capital Raise

Zoomcar Holdings completed the seventh closing of its private placement of Series A units, raising $75,000 in gross proceeds. Each unit consists of one share of Series A Convertible Preferred Stock and a warrant to purchase 20,000 shares of common stock. The offering has a total capacity of up to $5 million, plus a $5 million overallotment option, and has been extended to November 16, 2026.

5:20 PM ET 8-K
Nasdaq/NYSE Compliance Notice Aldel Financial II Inc. ALDFF

Aldel Financial II Nasdaq/NYSE Compliance Notice

Aldel Financial II Inc. received a delisting notice from Nasdaq on October 28, 2026, with trading of its securities expected to be suspended on November 6, 2026, due to failure to meet listing requirements. Separately, the company issued a $1.0 million unsecured promissory note to its sponsor, Aldel Investors II LLC, to fund working capital and trust account extension payments.

Counterparty
Aldel Investors II LLC
Term
through initial business combination
5:16 PM ET 8-K
Capital Raise Prokidney Corp. PROK

Prokidney Capital Raise

ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) offering program. Under the agreement, the company may offer and sell shares of its Class A common stock with a maximum aggregate offering price of up to $200 million. Jefferies will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds from any shares sold.

Counterparty
Jefferies LLC
5:08 PM ET 8-K
Capital Raise Meta Platforms, Inc. META

Meta Platforms Capital Raise of $12.5B

Meta Platforms, Inc. completed a public offering of 250,000,000 depositary shares, each representing a 1/20th interest in its 6.50% Series A Mandatory Convertible Preferred Stock. The offering raised $12.5 billion in gross proceeds (based on the $1,000 liquidation preference per full preferred share) to be used for general corporate purposes. The underwriters were granted a 30-day option to purchase an additional 37.5 million depositary shares to cover over-allotments.

Value
$12.5B
Counterparty
Morgan Stanley & Co. LLC
5:08 PM ET 8-K
M&A Deal Verisk Analytics, Inc. VRSK

Verisk Analytics M&A Deal with ExactLogix, Inc.

Verisk Analytics issued a status update regarding its pending acquisition of AccuLynx following a Delaware Supreme Court order that affirmed a previous Chancery Court judgment. The company stated it will proceed in accordance with the court's order, though the transaction remains subject to FTC review and customary closing conditions.

Counterparty
ExactLogix, Inc. (d/b/a AccuLynx.com)
5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice Propanc Biopharma, Inc. PPCB

Propanc Biopharma Nasdaq/NYSE Compliance Notice

Propanc Biopharma received a delisting notice from Nasdaq on October 23, 2026, for failing to maintain the $1.00 minimum bid price requirement. Because the company already completed a reverse stock split within the past year, it is ineligible for the standard 180-day grace period and faces delisting on November 2, 2026. The company intends to appeal the determination to a hearings panel, which will stay the delisting process.

Counterparty
Nasdaq
5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice Glucotrack, Inc. GCTK

Glucotrack Nasdaq/NYSE Compliance Notice

Glucotrack received notice from a Nasdaq Hearings Panel that its securities will be delisted after failing to maintain a $1.00 minimum bid price through the required exception period. Trading on Nasdaq will be suspended on October 30, 2026, and the company plans to transition its common stock to the OTC Markets Group (OTCID).

Counterparty
The Nasdaq Stock Market LLC
5:01 PM ET 8-K
Capital Raise BranchOut Food Inc. BOF

BranchOut Food Capital Raise of $5.75M

BranchOut Food Inc. completed its public offering following the full exercise of the underwriters' over-allotment option for 441,176 additional shares. The exercise generated $0.75 million in additional proceeds, bringing the total gross proceeds of the offering to approximately $5.75 million. The shares were sold at a public offering price of $1.70 per share.

Value
$5.75M
Counterparty
Lake Street Capital Markets LLC
5:01 PM ET 8-K
Clinical Trial Data Iovance Biotherapeutics, Inc. IOVA

Iovance Biotherapeutics Clinical Trial Data

Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.